NCT07101744View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: An Open-Label, Multicenter, Single-Arm Phase IIa Clinical Trial

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2025

Primary Completion Date

July 16, 2028

Study Completion Date

July 16, 2030

Conditions

Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma

Interventions

DRUG

Iparomlimab and Tuvonralimab

Iparomlimab and Tuvonralimab combined with Nimotuzumab , administered on Day 1 every 3 weeks (D1 Q3W), until disease progression or unacceptable toxicity.

Trial Locations (1)

Unknown

Sun Yat-sen University Cancer Center, Guangdong

All Listed Sponsors

lead

Sun Yat-sen University

OTHER